EverPoint Asset Management’s CoLucid Pharmaceuticals, Inc. CLCD Stock Holding History

EverPoint Asset Management’s Portfolio CLCD Stock Details CLCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-285,000	Closed	-$10.9M	–	599
2016 Q3	$10.9M	Sell	285,000 -43,979	-13%	-$650K	0.2%	135
2016 Q2	$2.69M	Sell	328,979 -27,763	-8%	-$186K	0.05%	301
2016 Q1	$2.21M	Buy	356,742 +138,693	+64%	+$866K	0.04%	326
2015 Q4	$1.82M	Buy	+218,049	New	+$1.15M	0.04%	385

Other funds holding CLCD

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

EverPoint Asset Management's CLCD Position: Q4 2016 in Review

EverPoint Asset Management sold out of CoLucid Pharmaceuticals, Inc. (CLCD) in Q4 2016, closing a stake of 285,000 shares — an estimated $10.9M sold.

EverPoint Asset Management first reported a position in CLCD in Q4 2015 and held it in 4 quarters. The position peaked at $10.9M in Q3 2016. 76 funds tracked by Wall St. Rank hold CLCD as of Q4 2016.

EverPoint Asset Management reported no remaining CoLucid Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
EverPoint Asset Management sold 285,000 CoLucid Pharmaceuticals, Inc. shares in Q4 2016, an estimated $10.9M.
EverPoint Asset Management first reported a position in CoLucid Pharmaceuticals, Inc. in Q4 2015 and held it in 4 quarters.
EverPoint Asset Management's CoLucid Pharmaceuticals, Inc. position peaked at $10.9M in Q3 2016.
76 funds tracked by Wall St. Rank held CoLucid Pharmaceuticals, Inc. as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.